Seneffe - Belgium, August 5th, 2014, Eckert & Ziegler BEBIG (Euronext: EZBG;
Reuters: EZBG.BR; Bloomberg: EZBG:BB) has announced today the publication of its
report on the first half-year results 2014. The report including a selection of
consolidated key figures for the six months ending June 30th, 2014 can be
www.bebig.eu > Investor Relations > Financial Reports
Eckert & Ziegler BEBIG
...Contributing to saving lives!
Eckert & Ziegler BEBIG, incorporated in 1996, is a European-based company active
in the medical device segment of the health care industry.
Eckert & Ziegler BEBIG's core business is the treatment of cancer using
brachytherapy, a special form of radiation therapy.
Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company
headquarters are in Belgium, with a production facility in both Germany and the
USA and subsidiaries throughout Europe as well as in India and Brazil. In
addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and
agents to support the international marketing of its product line.
The company's products and equipment are intended for use by oncologists,
radiologists, urologists, and medical physicists. Eckert & Ziegler BEBIG employs
more than 200 people. The company has been listed on the NYSE Euronext Brussels
stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg:
Eckert & Ziegler BEBIG s.a.
Tel.: +32 (0) 64 520 808
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Eckert & Ziegler BEBIG via GlobeNewswire